Last reviewed · How we verify
Tislelizumab and Bevacizumab — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Tislelizumab and Bevacizumab (Tislelizumab and Bevacizumab) — Second Affiliated Hospital of Nanchang University.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Tislelizumab and Bevacizumab TARGET | Tislelizumab and Bevacizumab | Second Affiliated Hospital of Nanchang University | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Tislelizumab and Bevacizumab CI watch — RSS
- Tislelizumab and Bevacizumab CI watch — Atom
- Tislelizumab and Bevacizumab CI watch — JSON
- Tislelizumab and Bevacizumab alone — RSS
Cite this brief
Drug Landscape (2026). Tislelizumab and Bevacizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/tislelizumab-and-bevacizumab. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab